News and Press Releases
Our Research Approach CF Foundation Invests up to $5M in Clarametyx Biosciences to Develop a New Anti-Bacterial Therapy 

Clarametyx’s novel therapy aims to disrupt bacterial biofilms, one of the primary causes of antibiotic resistance, thereby potentially increasing the effectiveness of existing treatments in fighting a wide range of bacterial infections, including those commonly affecting people with CF.

| 2 min read
Public Policy CF Foundation Grateful for Continued Access to Trikafta in Colorado After Prescription Drug Affordability Board’s Ruling

The Board’s review put Coloradans with CF at the center of the discussion, helping to preserve vital access to Trikafta®.

| 2 min read
Our Research Approach CF Foundation Invests Up to $3 Million in ViaNautis Bio to Explore a New Method to Deliver Genetic Therapies to People With CF

ViaNautis’ non-viral delivery mechanism, polyNaut®, aims to improve delivery of genetic therapies to the cells of people with CF. 

| 2 min read
About the CF Foundation | Diversity, Equity, and Inclusion CF Foundation Formalizes Final Set of Recommendations From External Racial Justice Working Group

The Foundation, in collaboration with external community advisors, finalizes recommendations in area of Community to help foster more inclusion and improve the experiences of Black people living with and impacted by cystic fibrosis.

| 4 min read
Diversity, Equity, and Inclusion | Our Research Approach CF Foundation Awards Advance Improvements in CF Newborn Screening

Since 2011, the Foundation has awarded $2.5 million across 35 different projects to improve cystic fibrosis newborn screening across the country.

| 4 min read
Our Research Approach CF Foundation Invests Up to $9 Million in Arcturus Therapeutics to Develop a Messenger RNA Therapy

The Cystic Fibrosis Foundation is providing additional funding to Arcturus Therapeutics to develop an inhaled messenger RNA therapy for CF that provides lung cells with the correct instructions to make functional cystic fibrosis transmembrane conductance regulator protein. The funding brings our total commitment to Arcturus to approximately $25 million.

| 3 min read
About the CF Foundation Cystic Fibrosis Foundation Announces New Members of Board of Trustees

Breadth of expertise in business, philanthropy, community engagement, and venture capital to help advance Foundation’s mission

| 4 min read
Get Involved Cystic Fibrosis Foundation Awards 2023 Impact Grants

To date, the CF Foundation has funded more than $1 million to programs created by and for the CF community.

| 5 min read
Our Research Approach CF Foundation Invests Up to $2 Million in Nosis Bio for Potential Gene Therapy Delivery Technology

Nosis Bio, an inaugural winner of the Foundation’s Golden Ticket Competition, receives funding to further explore design of novel ligands, which are specialized molecules that could help more precise targeting of relevant cells in the lung. 

| 3 min read
Advocacy | Antibiotics Adult with CF Provides Testimony at Congressional Hearing on the Impact of Antimicrobial Resistance 

Melanie Lawrence, an adult with cystic fibrosis, was selected to testify before a Senate Health, Education, Labor and Pensions subcommittee regarding the impact of antimicrobial resistance on patients who face heightened risk of infections, like those with CF.

| 3 min read